Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
Enzolytics (OTC PINK:ENZC) announced results from the Bulgarian Academy of Sciences' in vivo testing of Irreversible Pepsin Fraction (IPF) as an immunomodulator. The study, sponsored by Rosetta , found that IPF has a stimulating and modulating effect on innate and acquired immunity components, activating B, T, and NK cells, as well as macrophages. Notably, it increased B-regulatory cells, enhancing immune system control. The treatment showed no side effects, with 100% survival rate.
Additionally, a separate study by the Ministry of Health National Centre of Infectious and Parasitic Diseases in Bulgaria concluded that ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment is effective in decreasing growth and spread of various cancer cells, including breast, colon, prostate, larynx, and small cell lung cancer.
Enzolytics (OTC PINK:ENZC) ha annunciato i risultati dei test in vivo condotti dall'Accademia Bulgara delle Scienze sull'Irreversible Pepsin Fraction (IPF) come immunomodulatore. Lo studio, sponsorizzato da Rosetta, ha evidenziato che l'IPF ha un effetto stimolante e modulante sui componenti dell'immunità innata e acquisita, attivando le cellule B, T e NK, oltre ai macrofagi. In particolare, ha aumentato le cellule B-regolatorie, migliorando il controllo del sistema immunitario. Il trattamento non ha mostrato effetti collaterali, con un tasso di sopravvivenza del 100%.
Inoltre, uno studio separato del Ministero della Salute del Centro Nazionale per le Malattie Infettive e Parassitarie in Bulgaria ha concluso che il trattamento sperimentale di pepsina liofilizzata, con licenza esclusiva di ENZC, è efficace nel ridurre la crescita e la diffusione di vari tipi di cellule tumorali, inclusi il cancro al seno, al colon, alla prostata, della laringe e il cancro ai polmoni a piccole cellule.
Enzolytics (OTC PINK:ENZC) anunció los resultados de las pruebas in vivo realizadas por la Academia de Ciencias de Bulgaria sobre la Fracción Pepsina Irreversible (IPF) como inmunomodulador. El estudio, patrocinado por Rosetta, encontró que la IPF tiene un efecto estimulante y modulador sobre los componentes de la inmunidad innata y adquirida, activando células B, T y NK, así como macrófagos. Notablemente, aumentó las células B-reguladoras, mejorando el control del sistema inmunológico. El tratamiento no mostró efectos secundarios, con una tasa de supervivencia del 100%.
Además, un estudio separado realizado por el Ministerio de Salud del Centro Nacional de Enfermedades Infecciosas y Parasitarias de Bulgaria concluyó que el tratamiento experimental de pepsina liofilizada con licencia exclusiva de ENZC es efectivo para disminuir el crecimiento y la propagación de varias células cancerosas, incluyendo cáncer de mama, colon, próstata, laringe y cáncer de pulmón de células pequeñas.
Enzolytics (OTC PINK:ENZC)는 불가리아 과학 아카데미의 Irreversible Pepsin Fraction (IPF)에 대한 in vivo 테스트 결과를 발표했습니다. Rosetta가 후원한 이 연구는 IPF가 선천적 및 후천적 면역 구성 요소에 대해 자극 및 조절 효과가 있으며 B세포, T세포 및 NK세포와 대식세포를 활성화한다고 밝혔습니다. 특히, B-조절 세포가 증가하여 면역 체계의 조절 능력을 향상시켰습니다. 이 치료법은 부작용이 없었고, 100% 생존율을 보였습니다.
또한 불가리아 보건부 감염병 및 기생충 질환 국가 센터의 별도 연구에 따르면, ENZC의 독점 라이선스가 부여된 실험적 암 동결건조 펩신 치료가 여러 암 세포의 성장과 확산을 줄이는 데 효과적이라고 결론지었습니다. 여기에는 유방암, 대장암, 전립선암, 후두암 및 소세포 폐암이 포함됩니다.
Enzolytics (OTC PINK:ENZC) a annoncé les résultats des tests in vivo effectués par l'Académie Bulgare des Sciences sur la Fraction de Pepsine Irréversible (IPF) en tant qu'immunomodulateur. L'étude, sponsorisée par Rosetta, a révélé que l'IPF a un effet stimulant et modulant sur les composants de l'immunité innée et acquise, activant les cellules B, T et NK ainsi que les macrophages. Notamment, elle a augmenté le nombre de cellules B-régulatrices, renforçant le contrôle du système immunitaire. Le traitement n'a montré aucun effet secondaire, avec un taux de survie de 100%.
De plus, une étude distincte réalisée par le Ministère de la Santé au Centre National des Maladies Infectieuses et Parasitaires en Bulgarie a conclu que le traitement expérimental de pepsine lyophilisée, sous licence exclusive de l'ENZC, est efficace pour diminuer la croissance et la propagation de diverses cellules cancéreuses, y compris le cancer du sein, du côlon, de la prostate, du larynx et le cancer du poumon à petites cellules.
Enzolytics (OTC PINK:ENZC) gab die Ergebnisse der in vivo-Tests der Bulgarischen Akademie der Wissenschaften zur Irreversible Pepsin Fraction (IPF) als Immunomodulator bekannt. Die Studie, die von Rosetta gesponsert wurde, ergab, dass die IPF eine anregende und modulierende Wirkung auf die Komponenten der angeborenen und erworbenen Immunität hat, indem sie B-, T- und NK-Zellen sowie Makrophagen aktiviert. Auffällig war, dass die B-regulatorischen Zellen erhöht wurden, was die Kontrolle des Immunsystems verbesserte. Die Behandlung zeigte keine Nebenwirkungen, mit einer Überlebensrate von 100%.
Darüber hinaus kam eine separate Studie des Ministeriums für Gesundheit des Nationalen Zentrums für Infektions- und Parasitenkrankheiten in Bulgarien zu dem Schluss, dass die exklusiv lizenzierte experimentelle krebsbekämpfende gefriergetrocknete Pepsinbehandlung von ENZC wirksam zur Verringerung des Wachstums und der Ausbreitung verschiedener Krebszellen ist, einschließlich Brust-, Kolon-, Prostata-, Kehlkopf- und kleinzelligem Lungenkrebs.
- IPF demonstrated stimulating and modulating effects on innate and acquired immunity components
- No side effects observed with 100% survival rate in animal studies
- Increased B-regulatory cells, enhancing immune system control
- Experimental cancer treatment shown effective against multiple cancer types in vitro
- Potential for reducing recovery times of cancer patients after conventional treatments
- None.
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT
ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, has issued its first report under the recently announced collaborative agreement executed on September 9, 2024. The purpose of the study, which was sponsored by Rosetta, LLC, was to ascertain any pathological deviations as a result of the use of ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment's key active ingredient, Irreversible Pepsin Fraction ("IPF"), on the Kidney, Liver, Lymph Nodes and Spleen, measure the increased activation of the immune system, determine any side effects from the use of the compound and establish survivability of the animals (mouse model on Balb/c inbred mouse line under specific pathogen free sterile conditions) used in the study.
The sponsor of the study, Rosetta, LLC was awarded a licensing agreement by Zhabilov Trust for the production and distribution of IPF in spray form in the EU under the name Enzoimmune Active. ENZC will have the rights to North American markets.
The immunostimulatory testing consisted of a series of experiments to test IPF under In Vivo conditions for stimulation of specific clones of the immune system, as well as various pathophysiological indicators concerning the condition of the organs and evaluation of the survival of the treated animals with different regimes of the therapy making it possible to find the optimal conditions for treatment.
The results of the conducted experiments provided multifaceted information on the intimate mechanisms of activation and interaction between individual components of the immune system (humeral and cellular clone), as well as on interaction between innate and acquired immunity in general. One of the most significant findings was the increase in the amount of B- regulatory cells, a main factor for increased control over the functions of the immune system.
The report concludes, in summary, it can be said that IPF has a stimulating and modulating effect on the components of cell populations that make up innate and acquired immunity. The preparation activates a number of cohorts of B, T and NK cells, as well as macrophages. The regulatory elements are generates, as well as the synthesis of antibodies. There were no side effects or adverse reactions, with a
In the second group, representing a 10-day course of therapy and two-time introduction of IPF, the treatment showed the best qualities in terms of complex action on the individual components. Modulating action on these, more essential autoreactive processes can be obtained by oral intake in men and women. The data obtained so far give us reason to conclude that children's intake of reduced doses of IPF would have a positive effect on the immune system without any expectation of side effects.
This report follows on the statement published on the study conducted by the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria which concluded that inventor Harry Zhabilov's patented experimental cancer lyophilized pepsin treatment, exclusively licensed to Enzolytics, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer.
The Conclusion of the report by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, in its entirety reads as follows:
"A polypeptide complex of lyophilized pepsin, causes cytopathological changes and significantly reduces the survival and/or proliferative activity of the cell cultures used as experimental models. The tested substance exhibits the strongest cytotoxic/cytostatic effect on mammary adenocarcinoma (MCF-7 and MDA-MB-231 lines), cervical carcinoma (HeLa line), colorectal carcinoma (CaCo-2 line) and adenocarcinoma of the prostate (PC-3). A cytotoxic/cytostatic effect was observed on cells from small cell lung cancer (A 549 line) and the line Hep-2 (carcinoma of the larynx). The observed effect was time and concentration dependent, a response that is most likely due to the different biological characteristics of the malignant neoplasms from which the model cell lines were derived, as well as to the phenomenon of heterogeneity of tumor cells.
In conclusion, lyophilized pepsin has extremely promising biomedical potential."
Harry Zhabilov, Chief Science Officer of both ENZC and Sagaliam Acquisition Corp (SAGA) stated, "This initial report prepared by the Bulgarian Academy of Science on IPF and the statement by the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria on patented experimental cancer lyophilized pepsin treatment demonstrates the validity and value of our science. The stimulating and modulating effects on the immune system by IPF, we believe, will also be shown to reduce the recovery times of cancer patients after receiving radiation, chemotherapy and other treatments."
Steve Sharabura, the CEO of Enzolytics commented, "The fact that our cancer treatment has been shown in an in-vitro test to significantly reduce the survival and/or the proliferation of the cell cultures is encouraging. The in vivo test results showing IPF's stimulating and modulating effect on the components of cell populations that make up innate and acquired immunity is truly an inflexion point for the ENZC shareholder value moving forward."
Mr. Sharabura also stated that "There is another ridiculous attempt being made by Savov Dimatar today to try to disrupt the progress being made by ENZC and Sagaliam Acquisition Corp ("SAGA") on their license of patented products owned by Zhabilov Trust by declaring a shareholder meeting of IMMB BG to expel IMMB USA as an owner of IMMB BG. The
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from solely a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted service areas of sales, marketing and distribution focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
1101 Raintree Circle, Suite 130
Allen, Texas 75013
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
View the original press release on accesswire.com
FAQ
What were the key findings of the Bulgarian Academy of Sciences' study on ENZC's IPF?
How did ENZC's experimental cancer treatment perform in the study by the National Centre of Infectious and Parasitic Diseases?
What potential benefits does ENZC's IPF treatment offer for cancer patients?
What is the current status of ENZC's licensing agreement for IPF distribution?
